

A²
Appl. No. : Not yet assigned
Filed : Herewith

75. (NEW) The pharmaceutical composition of Claim 74, wherein said composition is stabilized by lyophilization and dissolves promptly upon reconstitution to provide solutions suitable for parenteral administration.

cont.

76. (NEW) The pharmaceutical composition of Claim 74, wherein said composition is stabilized by lyophilization and dissolves promptly upon reconstitution to provide solutions suitable for administration through inhalation.

REMARKS

By present amendments, Applicants have incorporated into the specification a paragraph indicating that the present application is a divisional of a pending U.S. application, to which the present application claims priority. Applicants have also included a new set of claims to be examined with this application. The new claims are drawn to the subject matter of the Group III claims, as set forth in the Restriction Requirement of March 21, 2001 in the parent case. Applicants maintain that the new claims add no new matter and are fully supported by the specification. By these amendments, Applicants make no admission as to the patentability of the original claims and the amendments should not be so construed.

Applicants maintain that the claims as presented herewith are allowable. A notice to that effect is respectfully requested.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 1, 2001

By: Sam K. Tahmassebi

Sam K. Tahmassebi
Registration No. 45,151
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660

AMEND

S:\DOCS\SKT\SKT-1297.DOC
041601